Pharmaceutical companies including Novartis and Roche have teamed up with global cancer organizations in an alliance aimed at getting more oncology medications to poorer countries.
In recent months, the biotech and biopharma industries have been struggling with layoffs and dropping stocks. However, some companies are still experiencing success. Sanofi, AstraZeneca, Avillion and Diadem recently announced positive clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee is holding a meeting on April 21, 2022, to discuss safety findings across the entire class of PI3K inhibitors for hematological cancers.
The European Medicines Agency on March 25 recommended the use of Johnson & Johnson and partner Legend Biotech Corp.’s CAR-T therapy Carvykti to treat multiple myeloma, nearly a month after the treatment was cleared in the United States.
The COVID-19 pandemic that became evident in the United States in early 2020 had a profound and disruptive effect upon cancer research and treatment, but the lessons learned can be used to improve healthcare delivery in multiple indications, according to the AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care that was released February 9th.
The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Biologics License Application (BLA) for teclistamab to the U.S. Food and Drug Administration for relapsed or refractory multiple myeloma.
Hundreds of updates were provided on clinical trials and preclinical research at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.
Coronavirus vaccines are known to be less protective in people with the blood cancer multiple myeloma, such as former U.S. Secretary of State Colin Powell, who died on Oct. 18 of complications from Covid-19 despite being fully vaccinated. Additionally, in a paper in the journal Stem Cell Reports, researchers said numerous businesses have made unsubstantiated and inaccurate claims about supposed stem cell products to treat Covid-19.
Pfizer is buying Toronto and Cambridge, Massachusetts-based Trillium Therapeutics in a deal worth $2.26 billion. Trillium focuses on developing a new set of checkpoint inhibitors to treat cancer.
The European Commission granted Conditional Marketing Authorization for Bristol Myers Squibb’s Abecma (idecabtagene vicleucel; ide-cel) – a first-in-class B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy – for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
